Search results
-
Toyota Kirloskar Motors: Evaluating a CSR Project
Utkarsh Majmudar; Namrata RanaCase IVEY-9B19M043-EStrategyToyota Kirloskar Motor Company Private Limited (TKM) was a leading car manufacturer in India, one engaged in a significant level of corporate social responsibility activities. TKM focused on health and hygiene issues in rural and semi-urban districts in India, as sanitation was a significant concern there. TKM's efforts to facilitate the improvement of health and hygiene among its program beneficiaries had met with considerable success. The compa...Starting at €8.20
-
Ambuja Cement: Measuring the Value of Water
Utkarsh Majmudar; Namrata RanaCase IVEY-9B17M129-EStrategyIn 2016, Ambuja Cements Limited (Ambuja Cement) was one of the largest cement companies in India. Company operations required the use of water for cooling, dust suppression, and domestic needs, but the use of water stressed the water resources at some of the company’s locations. Ambuja Cement thus identified the availability of water as a risk area for the organization and made water conservation a key element of their sustainability agenda. By v...Starting at €8.20
-
Bet on One Big Idea--or Diversify? (HBR Case Study and Commentary)
Stuart, TobyArticle HBS-R1311M-EStrategyA unique probiotic formulation, L-39, has great promise as a pharmaceutical treatment for a common illness. When it hits a stumbling block in its latest clinical trial, Hilde Dach, the scientist leading the research at German drug maker Caliska, faces the prospect that the company may want to reimagine her product as a nutraceutical, because the regulatory hurdles would be easier to clear. Is the company merely hedging its bets to avoid big losse...Starting at €8.20
-
Cadbury Schweppes: Capturing Confectionery (D)
Collis, David J.; Stuart, Toby; Smith, TroyCase HBS-708491-EStrategyIn late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing especially on chocolate and gum; and details the a...Starting at €5.74
-
Building Sustainability and Circularity at JSW Steel - Teaching Note
Utkarsh Majmudar; Namrata RanaTeaching Note IVEY-W26536-EStrategyTeaching note for product W26535.Starting at €0.00
-
Finolex: Developing an Integrated Corporate Social Responsibility Strategy - Teaching Note
Utkarsh Majmudar; Namrata RanaTeaching Note IVEY-8B17M098-EStrategyTeaching note for product 9B17M098.Starting at €0.00
-
Dalmia Bharat: Social Return on Investment - Teaching Note
Utkarsh Majmudar; Namrata RanaTeaching Note IVEY-8B17M165-EStrategyTeaching note for product 9B17M165.Starting at €0.00
-
GHCL Limited: Selling The Rekoop Story - Teaching Note
Utkarsh Majmudar; Namrata RanaTeaching Note IVEY-8B19M079-EStrategyTeaching note for product 9B19M079.Starting at €0.00
-
Bet on One Big Idea--or Diversify (HBR Case Study)
Stuart, TobyArticle HBS-R1311X-EStrategyA unique probiotic formulation, L-39, has great promise as a pharmaceutical treatment for a common illness. When it hits a stumbling block in its latest clinical trial, Hilde Dach, the scientist leading the research at German drug maker Caliska, faces the prospect that the company may want to reimagine her product as a nutraceutical, because the regulatory hurdles would be easier to clear. Is the company merely hedging its bets to avoid big losse...Starting at €8.20
-
Bet on One Big Idea--or Diversify (Commentary for HBR Case Study)
Stuart, TobyArticle HBS-R1311Z-EStrategyA unique probiotic formulation, L-39, has great promise as a pharmaceutical treatment for a common illness. When it hits a stumbling block in its latest clinical trial, Hilde Dach, the scientist leading the research at German drug maker Caliska, faces the prospect that the company may want to reimagine her product as a nutraceutical, because the regulatory hurdles would be easier to clear. Is the company merely hedging its bets to avoid big losse...Starting at €8.20